Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Abstract:
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has been selected by the American Society of Clinical Oncology (ASCO) to present data from its clinical trial evaluating NBTXR3 in advanced soft tissue sarcoma.

Nanobiotix Selected to Present Data from NBTXR3 Clinical Trial at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Paris, France | Posted on April 2nd, 2014

The clinical trial will be presented during the congress session dedicated to sarcoma.

This year's ASCO will take place in Chicago from 31 May to 3 June, 2014. The Annual Meeting brings together more than 25,000 oncology professionals from a broad range of clinical research specialties.

The NBTXR3 study was selected from over 5,500 abstracts received by the Scientific Program Committee of ASCO for review.

Laurent Levy, CEO of Nanobiotix said: "We are honored that ASCO has invited us to present our NBTXR3 data in front of the international oncology community. This is an encouraging step for our team and our partners and we will continue to develop innovative therapies aimed to improve patient care in the fight against cancer."

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

Issued for and on behalf of Nanobiotix by Instinctif Partners.

Disclaimer

This press release and the information contained therein do not constitute an offer of securities for sale or any solicitation to purchase or subscribe for Nanobiotix's shares in any jurisdiction. The distribution of this press release in certain jurisdictions may constitute a breach of applicable laws and regulations. Therefore, individuals who are located in such jurisdictions where this press release is issued, published or distributed must seek information and comply with such laws and regulations.

For more information, please click here

Contacts:
Nanobiotix
Sarah Gaubert
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55


NewCap.
Financial communication
and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53



Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)6 88 20 35 59



Instinctif Partners (formerly College Hill)
Media relations (Outside France)
Melanie Toyne Sewell / Donia Al Saffar / Katherine Lynch
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Throwing new light on printed organic solar cells December 1st, 2016

Nanomedicine

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016

Nanotechnology Treatment Found to Inhibit Mesothelioma Tumor Growth November 16th, 2016

Announcements

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Quantum obstacle course changes material from superconductor to insulator December 1st, 2016

Throwing new light on printed organic solar cells December 1st, 2016

Events/Classes

IEDM: Leti CEO Marie Semeria to Give Opening-day Keynote on Impact of ‘Hyperconnectivity’ and IoT: Speech to Portray Key Role Nonprofit Research and Technology Organizations Play in Making Technology More Efficient and Ensuring Safety and Security November 29th, 2016

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Cutting-edge nanotechnologies are breaking into industries November 18th, 2016

IEDM: CEO Marie Semeria to Deliver Opening Day Keynote at IEDM 2016; Institute to Present 13 Papers November 17th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project